BioMarin Pharmaceuticals Inc
BMRNBioMarin Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases. Founded in 1997, it specializes in treatments for conditions such as enzyme deficiencies, genetic disorders, and other underserved medical needs, offering its products primarily in the areas of neurology, inherited metabolic disorders, and hematology.
Company News
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...
BioMarin Pharmaceutical's Phase 3 CANOPY-HCH-3 study for VOXZOGO demonstrated a statistically significant 2.33 cm/year increase in annualized growth velocity for hypochondroplasia treatment, meeting its primary endpoint. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026. The stock surged 8.05% to $54.24 on the ...
CIBRA Capital significantly increased its stake in Amicus Therapeutics by 1.48 million shares worth $21.17 million during Q1 2026, making it the fund's largest position at 11.78% of AUM. The investment is a merger arbitrage bet on BioMarin Pharmaceutical's $14.50 per share acquisition offer, with potential $0.20 per share profit if the deal compl...
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinic...
Vestal Point Capital sold 1.054 million shares of Nuvalent (NUVL) for approximately $103.93 million in Q4, reducing its position to less than 1% of assets under management. Despite the sale, Nuvalent shares have rallied nearly 30% over the past year and the company is well-positioned financially with $1.4 billion in cash, awaiting potential FDA d...
